ArticleDiagnostics (Basel, Switzerland)2021
Delta Radiomics Analysis for Local Control Prediction in Pancreatic Cancer Patients Treated Using Magnetic Resonance Guided Radiotherapy.
Article in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Artificial intelligence applied to image-guided radiation therapy (IGRT): a systematic review by the Young Group of the Italian Association of Radiotherapy and Clinical Oncology (yAIRO).La Radiologia medica · 2024Pooled it
- Role of radiomics in predicting lymph node metastasis in gastric cancer: a systematic review.Frontiers in medicine · 2023Pooled it
- Delta radiomics: a systematic review.La Radiologia medica · 2021Pooled it
- Predictive value of 18F-FDG PET/CT delta radiomics model for prognosis after neoadjuvant therapy for locally advanced pancreatic cancer.Frontiers in oncology · 2026Article
- Visualization-driven digital technologies in oncology: current applications, technological advances, and future directions.Frontiers in oncology · 2026Review
- An interpretable delta ultrasound radiomics model for predicting live birth outcomes in single vitrified-warmed blastocyst transfer.Journal of ovarian research · 2025Article
- Clinical Applications of Quantitative Imaging and Artificial Intelligence for Pancreatic Cance.Seminars in radiation oncology · 2025Review
- AI-Driven insights in pancreatic cancer imaging: from pre-diagnostic detection to prognostication.Abdominal radiology (New York) · 2025Review
- Magnetic Resonance-Guided Cancer Therapy Radiomics and Machine Learning Models for Response Prediction.Tomography (Ann Arbor, Mich.) · 2024Review
- Stereotactic body radiation therapy for the primary tumor and oligometastases versus the primary tumor alone in patients with metastatic pancreatic cancer.Radiation oncology (London, England) · 2024Article
- Delta radiomics to track radiation response in lung tumors receiving stereotactic magnetic resonance-guided radiotherapy.Physics and imaging in radiation oncology · 2024Article
- Robustness of radiomics features on 0.35 T magnetic resonance imaging for magnetic resonance-guided radiotherapy.Physics and imaging in radiation oncology · 2024Article
- Radiomics-enhanced early regression index for predicting treatment response in rectal cancer: a multi-institutional 0.35 T MRI-guided radiotherapy study.La Radiologia medica · 2024Article
- Magnetic Resonance Image Radiomic Reproducibility: The Impact of Preprocessing on Extracted Features from Gross and High-Risk Clinical Tumor Volumes in Cervical Cancer Patients before Brachytherapy.Journal of medical signals and sensors · 2024Article
- KIT 1 (Keep in Touch) Project-Televisits for Cancer Patients during Italian Lockdown for COVID-19 Pandemic: The Real-World Experience of Establishing a Telemedicine System.Healthcare (Basel, Switzerland) · 2023Article
- First treatments for Lattice stereotactic body radiation therapy using magnetic resonance image guided radiation therapy.Clinical and translational radiation oncology · 2023Article
- Integration of art and technology in personalized radiation oncology care: Experiences, evidence, and perspectives.Frontiers in public health · 2023Article
- The progress of PET/MRI in clinical management of patients with pancreatic malignant lesions.Frontiers in oncology · 2023Review
- Feasibility of delta radiomics-based pCR prediction for rectal cancer patients treated with magnetic resonance-guided adaptive radiotherapy.Frontiers in oncology · 2023Article
- Art and digital technologies to support resilience during the oncological journey: The Art4ART project.Technical innovations & patient support in radiation oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study is to investigate the role of Delta Radiomics analysis in the prediction of one-year local control (1yLC) in patients affected by locally advanced pancreatic cancer (LAPC) and treated using Magnetic Resonance guided Radiotherapy (MRgRT). A total of 35 patients from two institutions were enrolled: A 0.35 Tesla T2*/T1 MR image was acquired for each case during simulation and on each treatment fraction. Physical dose was converted in biologically effective dose (BED) to compensate for different radiotherapy schemes. Delta Radiomics analysis was performed considering the gross tumour volume (GTV) delineated on MR images acquired at BED of 20, 40, and 60 Gy. The performance of the delta features in predicting 1yLC was investigated in terms of Wilcoxon Mann-Whitney test and area under receiver operating characteristic (ROC) curve (AUC). The most significant feature in predicting 1yLC was the variation of cluster shade calculated at BED = 40 Gy, with a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.